EUVIMEDObjevte EUVIMED
Open access · CC BY 4.0

The fast‐dissociating D 2 antagonist antipsychotic JNJ‐37822681 is a neuronal Kv7 channel opener: Potential repurposing for epilepsy treatment

Lidia Carotenuto, Oliver Keminer, Giusy Carleo, Andrea Zaliani, Antonio Leo, Rita Citraro, Giovambattista De Sarro, Nina Dirkx, Marcus Kaji, Sarah Weckhuysen, Jeanette Reinshagen, Vincenzo Barrese and 5 more

British Journal of Pharmacology · 2025

DOI: 10.1111/bph.70119 ↗

At a glance

Journal article in British Journal of Pharmacology, 2025. Written by Lidia Carotenuto and 16 co-authors. Institution: Division of Pharmacology, Department of Neuroscience, University of Naples Federico II, Naples, Italy. Major MEDLINE topics: Anticonvulsants, Antipsychotic Agents, Neurons, Epilepsy. Cited 11 times so far (Crossref); 93 references. The full text is freely available (open access, CC BY 4.0). Funded by: Ministero dell'Università e della Ricerca, Compagnia di San Paolo, Queen Elisabeth Medical Foundation for Neurosciences.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background and Purpose Pharmacological activation of neuronal M‐current mediated by Kv7 (Kv7.2–5) potassium channels is a validated mechanism for epilepsy treatment. However, since the market withdrawal of the prototype Kv7 activator retigabine, no Kv7 activator is clinically available for this condition. The object was to identify, characterise and validate new neuronal Kv7 channel activators for epilepsy treatment. Experimental Approach A fluorescence‐based high‐throughput assay was optimised in cells stably expressing Kv7 channels to screen two repurposing libraries including >8000 compounds. Whole‐cell patch clamp, in silico docking, mutagenesis and multielectrode array recordings in human induced‐pluripotent stem cell (hiPSCs)‐derived cortical‐like glutamatergic neurons (iNeurons) were used to evaluate compound(s) potency and efficacy, binding site, and effects on neuronal activity, respectively. Finally, anticonvulsant activity was assessed in two acute seizure models in male mice. Key Results JNJ‐37822681, a fast‐dissociating D 2 receptor antagonist in clinical development as antipsychotic, enhanced Kv7.2–5 currents with potency and efficacy largely comparable to retigabine. In Kv7.2 subunits, JNJ‐37822681 binding site largely overlapped that for retigabine. In iNeurons, JNJ‐37822681 enhanced the M‐current, hyperpolarised the resting membrane potential and reduced spontaneous action potential firing. These effects were blocked by the Kv7 antagonist, XE‐991, and were not reproduced by the D 2 antagonist (‐)‐sulpiride. Finally, JNJ‐37822681 showed anticonvulsant activity in two well‐validated mouse models of acute seizures. Conclusions and Implications Our study reveals that JNJ‐37822681, which lacks retigabine's potential safety issues due to chemical liability and is already confirmed as safe for human use, represents a potential treatment of Kv7‐related neuronal hyperexcitability disorders.

Subjects

MeSH terms (MEDLINE)

AnticonvulsantsAntipsychotic AgentsNeuronsEpilepsyKCNQ Potassium ChannelsReceptors, Dopamine D2AnimalsHumansMaleMiceDrug RepositioningMice, Inbred C57BLMolecular Docking Simulation

Author keywords

antiseizure medicationsdrug repurposingepilesy, Kv7 channelsiPSC‐derived neuronsion channels

Substances

AnticonvulsantsAntipsychotic AgentsKCNQ Potassium ChannelsReceptors, Dopamine D2

Authors and institutions

  • Division of Pharmacology, Department of Neuroscience, University of Naples Federico II, Naples, Italy.
  • Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Discovery Research ScreeningPort, Hamburg, Germany.
  • Fraunhofer Cluster of Excellence for Immune-Mediated Diseases (CIMD), Frankfurt am Main, Germany.
  • Department of Health Sciences, Research Center FAS@UMG, University of Catanzaro, Catanzaro, Italy.
  • Applied and Translational Neurogenomics Group, VIB Center for Molecular Neurology, Antwerp, Belgium.
  • Department of Neurology, University Hospital Antwerp, Antwerp, Belgium.

ORCID profiles: Maurizio Taglialatela

Funding

  • Ministero dell'Università e della Ricerca
  • Compagnia di San Paolo
  • Queen Elisabeth Medical Foundation for Neurosciences
  • European Joint Programme on Rare Disease JTC 2020
  • CUP
  • Italian Ministry for University and Research (MUR)
  • Italian Ministry of Health (MoH)
  • Fonds Wetenschappelijk Onderzoek

Cite

APA

Carotenuto, L., Keminer, O., Carleo, G., Zaliani, A., Leo, A., Citraro, R., De Sarro, G., Dirkx, N., Kaji, M., Weckhuysen, S., Reinshagen, J., Barrese, V., Guida, N., Ostacolo, C., Miceli, F., Gribbon, P., & Taglialatela, M. (2025). The fast‐dissociating D 2 antagonist antipsychotic JNJ‐37822681 is a neuronal Kv7 channel opener: Potential repurposing for epilepsy treatment. British Journal of Pharmacology. https://doi.org/10.1111/bph.70119

Vancouver

Carotenuto L, Keminer O, Carleo G, Zaliani A, Leo A, Citraro R, et al. The fast‐dissociating D 2 antagonist antipsychotic JNJ‐37822681 is a neuronal Kv7 channel opener: Potential repurposing for epilepsy treatment. British Journal of Pharmacology. 2025. doi:10.1111/bph.70119

BibTeX
@article{Carotenuto2025,
  author = {Carotenuto, Lidia and Keminer, Oliver and Carleo, Giusy and Zaliani, Andrea and Leo, Antonio and Citraro, Rita and De Sarro, Giovambattista and Dirkx, Nina and Kaji, Marcus and Weckhuysen, Sarah and Reinshagen, Jeanette and Barrese, Vincenzo and Guida, Natascia and Ostacolo, Carmine and Miceli, Francesco and Gribbon, Philip and Taglialatela, Maurizio},
  title = {The fast‐dissociating D 2 antagonist antipsychotic JNJ‐37822681 is a neuronal Kv7 channel opener: Potential repurposing for epilepsy treatment},
  journal = {British Journal of Pharmacology},
  year = {2025},
  doi = {10.1111/bph.70119}
}
Start for free →